(Q81211630)
Statements
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis (English)
Alice B Gottlieb
Kenneth B Gordon
Mark G Lebwohl
Ivor Caro
Patricia A Walicke
Nicole Li
Craig L Leonardi
EFALIZUMAB STUDY GROUP